Loading
Latest filing published 13 Jun 2024 for Celldex Therapeutics, Inc., €38k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Diane C. Young in Celldex Therapeutics, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 12 November 2021 to 11 June 2024, the count stands at 4 filings.
No open-market purchase appears, only 1 sale worth €1.5M. Other entries cover 3 option exercises. In 2024 alone, the filings show no purchases and 1 sale.
On 13 June 2024 came the latest disclosure, an option exercise for €38k in Celldex Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations